The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N1-(2-methoxyethyl)-N6-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinoline-1,6-diamine ID: ALA4797966
PubChem CID: 162674608
Max Phase: Preclinical
Molecular Formula: C18H18N6O
Molecular Weight: 334.38
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COCCNc1nccc2cc(Nc3n[nH]c4cccnc34)ccc12
Standard InChI: InChI=1S/C18H18N6O/c1-25-10-9-21-17-14-5-4-13(11-12(14)6-8-20-17)22-18-16-15(23-24-18)3-2-7-19-16/h2-8,11H,9-10H2,1H3,(H,20,21)(H2,22,23,24)
Standard InChI Key: BPTCIHDKCDLGHQ-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 28 0 0 0 0 0 0 0 0999 V2000
28.9593 -3.7434 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9582 -4.5629 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6662 -4.9719 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6645 -3.3345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.3731 -3.7398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.3738 -4.5588 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0824 -4.9658 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.7906 -4.5550 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.7859 -3.7329 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.0768 -3.3295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.2502 -4.9709 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.5428 -4.5618 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.4569 -3.7511 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.6577 -3.5806 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.7949 -4.8956 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2511 -4.2880 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.4549 -4.4557 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.2015 -5.2306 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7504 -5.8380 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.5445 -5.6671 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.0725 -2.5123 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.7780 -2.1000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.7737 -1.2828 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.4792 -0.8705 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
32.4749 -0.0533 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
2 11 1 0
11 12 1 0
12 13 2 0
13 14 1 0
14 16 1 0
15 12 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 15 1 0
10 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 334.38Molecular Weight (Monoisotopic): 334.1542AlogP: 3.31#Rotatable Bonds: 6Polar Surface Area: 87.75Molecular Species: NEUTRALHBA: 6HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 12.89CX Basic pKa: 8.43CX LogP: 2.29CX LogD: 1.35Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.47Np Likeness Score: -1.29
References 1. Panarese JD,Engers DW,Wu YJ,Guernon JM,Chun A,Gregro AR,Bender AM,Capstick RA,Wieting JM,Bronson JJ,Macor JE,Westphal R,Soars M,Engers JE,Felts AS,Rodriguez AL,Emmitte KA,Jones CK,Blobaum AL,Conn PJ,Niswender CM,Hopkins CR,Lindsley CW. (2019) The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate., 29 (2.0): [PMID:30503632 ] [10.1016/j.bmcl.2018.10.050 ]